Free Trial

Evox Therapeutics (EVOXW) 10K Form and Latest SEC Filings 2026

Evox Therapeutics logo
$0.36 -0.01 (-1.35%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Evox Therapeutics SEC Filings & Recent Activity

Evox Therapeutics (NASDAQ:EVOXW) has submitted 22+ documents to the U.S. Securities and Exchange Commission (SEC) since 2025. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on March 13, 2026.

8-K
Evox Therapeutics Files Current Report on Mar. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Evox Therapeutics Files Annual Report on Mar. 3, 2026

The 10-K contains Evox Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Evox Therapeutics SEC Filing History

Browse Evox Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
03/13/2026 8:30 AM
Evox Therapeutics (2077954) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2026 2:57 PM
Evox Therapeutics (2077954) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/12/2026 8:02 AM
Adage Capital Management, L.P. (1535978) Filed by
Evox Therapeutics (2077954) Subject
Form SCHEDULE 13G
12/23/2025 4:58 PM
Evox Therapeutics (2077954) Subject
Linden Capital L.P. (1349339) Filed by
Form SCHEDULE 13G
12/16/2025 9:31 AM
Evox Therapeutics (2077954) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
12/02/2025 6:23 PM
Apter Gavin (2098730) Reporting
Evox Therapeutics (2077954) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/01/2025 3:17 PM
Evox Therapeutics (2077954) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/24/2025 12:34 PM
Evox Therapeutics (2077954) Subject
Evolution Sponsor Holdings LLC (2076725) Filed by
Form SCHEDULE 13G
11/18/2025 3:37 PM
Evox Therapeutics (2077954) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 8:07 PM
Evox Therapeutics (2077954) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2025 5:24 PM
Evox Therapeutics (2077954) Issuer
Silver Stephen Marc (2076727) Reporting
Form 3/A
11/12/2025 9:18 AM
Evox Therapeutics (2077954) Filer
Form 424B4
11/12/2025 6:36 AM
Evox Therapeutics (2077954) Filer
Form CERT
11/10/2025 5:21 PM
Chen Arthur Kuan-Lin (2077042) Reporting
Evox Therapeutics (2077954) Issuer
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:22 PM
Evox Therapeutics (2077954) Issuer
Evolution Sponsor Holdings LLC (2076725) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:22 PM
Evox Therapeutics (2077954) Issuer
Ichilov Erez (1883318) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:22 PM
Evox Therapeutics (2077954) Issuer
Langsford Matthew Ryan (2076589) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:22 PM
Evox Therapeutics (2077954) Issuer
Zumwalt-Forbes Ashley Elizabeth (2076466) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:23 PM
Evox Therapeutics (2077954) Issuer
Silver Stephen Marc (2076727) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/10/2025 5:06 PM
Evox Therapeutics (2077954) Filer
Form S-1MEF
10/22/2025 4:01 PM
Evox Therapeutics (2077954) Filer
Form S-1/A
07/31/2025 4:15 PM
Evox Therapeutics (2077954) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Evox Therapeutics SEC Filings - Frequently Asked Questions

Evox Therapeutics (EVOXW) has submitted 22+ filings to the SEC since 2025. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 8-K submitted on March 13, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:EVOXW) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners